Everest Medicines

Expanding Healthcare Access In China Will Enlarge Rare Disease Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

05 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

HK$79.89

12.2% undervalued

21 Aug

HK$70.15

279.2%

0.3%

Author's Valuation

HK$79.9

12.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

HK$79.9

12.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

30.49%

Biotech revenue growth rate

12.78%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.89%

Calculation

CN¥746.89m

Earnings '28

38.91x

PE Ratio '28

CN¥29.06b

Market Cap '28

CN¥29.06b

Market Cap '28

324.35m

No. shares '28

CN¥89.60

Share Price '28

CN¥89.60 Share Price '28

Discounted to 2025 @ 6.89% p.a.

CN¥73.37

Fair Value '25

CN¥73.37 Fair Value '25

Converted to HKD @ 1.0889 CNY/HKD Exchange Rate

HK$79.89

Fair Value '25